About 107 of these antigen-loaded DCs are injected intradermally back into the patient where they migrate to regional lymph nodes, guided by chemokine signals, and where they present tumor antigens to both CD8+ cytotoxic T cells and by cross-presentation to CD4+ helper T cells (see Section 2.2). Here, CD4 is linked to neoplasm.